Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
about
Aspirin use in myeloma: a note of caution regarding potential tumour necrosis factor-alpha elevationThrombosis in multiple myelomaAssessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot studyMonoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.The evolving use of serum free light chain assays in haematology.Thalidomide in multiple myeloma: past, present and future.Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.Review of thalidomide in the treatment of newly diagnosed multiple myeloma.Role of thalidomide in previously untreated patients with multiple myeloma.Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma.Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
P2860
Q28196519-D1F0E4F5-48B2-4F45-AF8F-7A6496C86D99Q28219961-C4F30F58-E2A8-4785-A853-767298FB869EQ33301492-753614B3-C4FB-4AAE-83AA-12FE9409B824Q34637209-BF5CB26E-5DFF-4978-BF30-1A9C442A1F74Q34758218-30617610-8846-4B94-A343-B53F3DC2AD34Q36616493-CE83BD62-D2E3-4CB1-87B9-A8640FDE872AQ36697556-25919E10-0E76-4A19-9964-2741592786A5Q37160347-DEA16E2F-9CB0-40A9-97CB-8DFAFFCA852DQ37300004-387A99E0-9F3F-488D-956B-7FF80C521CF6Q37831402-44EB7A12-CCFF-453A-9EBD-D2AB6F611FC9Q38832949-7D4A67FD-0512-4E17-9BC0-E5A682ED1713Q43921722-F63963A0-9FFE-45DC-A80B-2719A5998A0BQ52868558-EC93ABEB-CA49-4A61-81FB-91EABE6D363CQ53148481-566586CC-97AF-40A8-A1C2-785CC22F0C93
P2860
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Doxorubicin and dexamethasone ...... l therapy for multiple myeloma
@ast
Doxorubicin and dexamethasone ...... l therapy for multiple myeloma
@en
Doxorubicin and dexamethasone ...... l therapy for multiple myeloma
@nl
type
label
Doxorubicin and dexamethasone ...... l therapy for multiple myeloma
@ast
Doxorubicin and dexamethasone ...... l therapy for multiple myeloma
@en
Doxorubicin and dexamethasone ...... l therapy for multiple myeloma
@nl
prefLabel
Doxorubicin and dexamethasone ...... l therapy for multiple myeloma
@ast
Doxorubicin and dexamethasone ...... l therapy for multiple myeloma
@en
Doxorubicin and dexamethasone ...... l therapy for multiple myeloma
@nl
P2093
P2860
P1476
Doxorubicin and dexamethasone ...... l therapy for multiple myeloma
@en
P2093
Adam Cohen
Daniel A Filippa
Elyn R Riedel
Hani Hassoun
Lilian Reich
Lisa Drake
Madhav Dhodapkar
Martin Fleisher
Rachel Zimman
Raymond L Comenzo
P2860
P304
P356
10.1111/J.1365-2141.2005.05848.X
P407
P577
2006-01-01T00:00:00Z